New Therapy Options for Neuromyelitis Optica Spectrum Disorder: Eculizumab, Inebilizumab and Stralizumab for AQP4 Ab Positive NMOSD

41 views
July 23, 2021
Comments 0
Login to view comments. Click here to Login